Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $48.61 USD
Change Today +0.02 / 0.04%
Volume 646.2K
ALR On Other Exchanges
New York
As of 8:04 PM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

alere inc (ALR) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/2/15 - $54.58
52 Week Low
08/4/14 - $33.76
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ALERE INC (ALR)

alere inc (ALR) Related Businessweek News

View More BusinessWeek News

alere inc (ALR) Details

Alere Inc. provides point-of-care diagnostics and services for infectious disease, cardiometabolic disease, and toxicology in the United States and internationally. The company operates through Professional Diagnostics and Consumer Diagnostics segments. Its cardiometabolic products and services include tests to assist in the diagnosis and management of various cardiometabolic factors and conditions, including cardiac markers, glucose and HbA1C, cholesterol levels, blood gases, and home monitoring for VAD and oral anticoagulation. These meters and tests are used in hospital urgent care, laboratory, doctor’s office, or at home. The company’s infectious disease products and services comprise tests to assist in the diagnosis and management of infectious diseases, such as HIV, malaria, syphilis, E. coli, and influenza. The infectious disease diagnostic tests and monitoring devices provide results for approximately 75 types of infectious diseases, including those caused by bacteria, viruses, fungi, or parasites. Its drug and alcohol testing portfolio includes rapid analyzer-based tests, visual-read screening devices, laboratory tests, and immunoassay reagents. The company’s toxicology products are used in hospitals, clinics, physician offices, criminal justice systems, workplace, rehabilitation, occupational health clinics, home testing, and other. Alere Inc. also delivers services and solutions across various environments, including clinical immunology, women's health, and oncology. It markets its professional diagnostic products through its sales force and distribution networks; and First Check consumer drug testing products through retail drug stores, drug wholesalers, groceries, and mass merchandisers. The company was formerly known as Inverness Medical Innovations, Inc. and changed its name to Alere Inc. in July 2010. Alere Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts.

9,800 Employees
Last Reported Date: 05/28/15
Founded in 1981

alere inc (ALR) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $882.1K
Global President of Toxicology
Total Annual Compensation: $650.0K
Global President of Cardiometabolic Business ...
Total Annual Compensation: $548.1K
Global President of Infectious Disease Busine...
Total Annual Compensation: $486.3K
Executive officer
Total Annual Compensation: $425.1K
Compensation as of Fiscal Year 2014.

alere inc (ALR) Key Developments

Alere Inc. Appoints Geoffrey S. Ginsburg to the Company's Board of Directors

Alere Inc. announced the election of Geoffrey S. Ginsburg, M.D., Ph.D. to the Company's Board of Directors, effective immediately. Dr. Ginsburg is a founding director of the Center for Applied Genomics & Precision Medicine and also a professor of Medicine, Pathology and Biomedical Engineering, both at Duke University. In addition to his current positions at Duke University, Dr. Ginsburg also serves as an expert panel member for Genome Canada, as a member of the Board of External Experts for the National Heart, Lung and Blood Institute, as Co-Chair of the Institute of Medicine's Roundtable on Genome-Based Research to Human Health, as a member of the advisory council for the National Center for Accelerating Translational Science, as co-Chair of the Cures Acceleration Network, co-chair of the Global Genomic Medicine Collaborative, and as a member of the World Economics Forum'sGlobal Agenda Council on the Future of the Health Sector.

Alere Inc. Receives U.S. Food and Drug Administration CLIA Waiver for Alere i Strep A Rapid Molecular Test

Alere Inc. announced that the U.S. Food and Drug Administration (FDA) has granted CLIA waiver for the Alere™ i Strep A test. The test, which was cleared for marketing by the FDA in April 2015, is the first molecular platform that detects Group A Streptococcus (GAS) bacteria in 8 minutes or less. With CLIA waiver, the Alere i Strep A test will be available in a broad range of healthcare settings, including physician offices, hospital emergency rooms, and retail and walk-in clinics in the United States. The Strep A test is the second assay on the Alere i molecular platform, which initially received 510(k) clearance for the detection and differentiation of influenza A and B virus in 2014. In January 2015, Alere i Influenza A & B became the first-ever molecular test to receive CLIA waiver.

Alere Inc. Announces Completion of Offering of $425 Million of Senior Subordinated Notes

Alere Inc. announced that it has completed its previously announced offering of $425 million of senior subordinated notes. The notes will bear interest at a rate of 6.375% per year, payable semi-annually on January 1 and July 1 of each year, beginning on January 1, 2016, and will mature on July 1, 2023 unless earlier redeemed. The company intends to use the net proceeds from the offering to redeem, effective as of October 1, 2015, all of its outstanding $400 million aggregate principal amount of 8.625% senior subordinated notes due 2018 and to pay a portion of related redemption fees, premiums, costs and expenses and accrued interest on such notes. The company exercised its right immediately to satisfy and discharge all of its obligations with respect to the 8.625% senior subordinated notes, subject to settlement of the redemption on October 1, 2015. As a result of this refinancing, the company expects to save approximately $2 million in quarterly interest expense.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ALR:US $48.61 USD +0.02

ALR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bio-Rad Laboratories Inc $150.74 USD -0.07
BioMerieux €105.60 EUR -0.55
Hill-Rom Holdings Inc $56.03 USD +0.66
PerkinElmer Inc $52.92 USD +1.50
STERIS Corp $69.13 USD +0.44
View Industry Companies

Industry Analysis


Industry Average

Valuation ALR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.6x
Price/Book 2.8x
Price/Cash Flow 23.4x
TEV/Sales NM Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALERE INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at